A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma

BACKGROUND: Flavopiridol, a Cdk inhibitor, potentiates irinotecan-induced apoptosis. In a phase I trial of sequential irinotecan and flavopiridol, 2 patients with advanced hepatocellular carcinoma (HCC) had stable disease (SD) for ≥14 months. We thus studied the sequential combination of irinotecan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ang, Celina, O'Reilly, Eileen M., Carvajal, Richard D., Capanu, Marinela, Gonen, Mithat, Doyle, Laurence, Ghossein, Ronald, Schwartz, Lawrence, Jacobs, Gria, Ma, Jennifer, Schwartz, Gary K., Abou-Alfa, Ghassan K.
Formato: Artigo
Idioma:Inglês
Publicado em: International Society of Gastrointestinal Oncology 2012
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3533846/
https://ncbi.nlm.nih.gov/pubmed/23293699
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados